DZ2913A1 - Composition pharmaceutique concentrée liquide de sertraline et procédé pour sa préparation. - Google Patents

Composition pharmaceutique concentrée liquide de sertraline et procédé pour sa préparation.

Info

Publication number
DZ2913A1
DZ2913A1 DZ990213A DZ990213A DZ2913A1 DZ 2913 A1 DZ2913 A1 DZ 2913A1 DZ 990213 A DZ990213 A DZ 990213A DZ 990213 A DZ990213 A DZ 990213A DZ 2913 A1 DZ2913 A1 DZ 2913A1
Authority
DZ
Algeria
Prior art keywords
sertraline
preparation
pharmaceutical composition
liquid concentrated
concentrated pharmaceutical
Prior art date
Application number
DZ990213A
Other languages
English (en)
Inventor
Nancy Jane Harper
Ranade Gautam Ramchandra
Welch Willard Mckowan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22298286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2913(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2913A1 publication Critical patent/DZ2913A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DZ990213A 1998-10-13 1999-10-12 Composition pharmaceutique concentrée liquide de sertraline et procédé pour sa préparation. DZ2913A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10402498P 1998-10-13 1998-10-13

Publications (1)

Publication Number Publication Date
DZ2913A1 true DZ2913A1 (fr) 2004-03-01

Family

ID=22298286

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990213A DZ2913A1 (fr) 1998-10-13 1999-10-12 Composition pharmaceutique concentrée liquide de sertraline et procédé pour sa préparation.

Country Status (45)

Country Link
EP (1) EP1121107B1 (fr)
JP (1) JP3792514B2 (fr)
KR (1) KR100417200B1 (fr)
CN (1) CN1184962C (fr)
AP (1) AP2001002119A0 (fr)
AR (1) AR014082A1 (fr)
AT (1) ATE254453T1 (fr)
AU (1) AU766202B2 (fr)
BG (1) BG65085B1 (fr)
BR (1) BR9914418A (fr)
CA (1) CA2346335C (fr)
CO (1) CO5150213A1 (fr)
CZ (1) CZ20011286A3 (fr)
DE (1) DE69912978T2 (fr)
DK (1) DK1121107T3 (fr)
DZ (1) DZ2913A1 (fr)
EA (1) EA003990B1 (fr)
EE (1) EE04868B1 (fr)
EG (1) EG23818A (fr)
ES (1) ES2209490T3 (fr)
GC (1) GC0000175A (fr)
GE (1) GEP20032969B (fr)
GT (1) GT199900171A (fr)
HK (1) HK1040199B (fr)
HR (1) HRP20010263B1 (fr)
HU (1) HUP0104470A3 (fr)
ID (1) ID29845A (fr)
IS (1) IS2239B (fr)
MA (1) MA26698A1 (fr)
MY (1) MY122477A (fr)
NO (1) NO20011829L (fr)
NZ (1) NZ510756A (fr)
OA (1) OA11662A (fr)
PA (1) PA8483301A1 (fr)
PE (1) PE20001108A1 (fr)
PL (1) PL348119A1 (fr)
PT (1) PT1121107E (fr)
SK (1) SK4582001A3 (fr)
TN (1) TNSN99190A1 (fr)
TR (1) TR200101090T2 (fr)
TW (1) TWI228043B (fr)
UA (1) UA72743C2 (fr)
WO (1) WO2000021521A2 (fr)
YU (1) YU26401A (fr)
ZA (1) ZA200102900B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05315B1 (et) 1999-09-03 2010-08-16 Eli Lilly And Company Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2004065348A1 (fr) * 2003-01-23 2004-08-05 Pfizer Products Inc. Sels pharmaceutiquement acceptables de sertraline et compositions pharmaceutiques correspondantes
WO2005000786A1 (fr) * 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Compositions de sertraline
WO2005034910A1 (fr) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Compositions pharmaceutiques liquides de sertraline a administration orale
WO2007052152A2 (fr) * 2005-11-07 2007-05-10 Aurobindo Pharma Limited Concentré oral d'un antidépresseur
WO2008112641A2 (fr) * 2007-03-09 2008-09-18 New York University Procédés et compositions pour le traitement de la dysrythmie thalamocorticale
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
DE69004529T2 (de) * 1989-08-30 1994-02-24 Pfizer Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
CA2143070C (fr) * 1994-02-22 2001-12-18 Pankaj Modi Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
SE508372C2 (sv) * 1995-02-13 1998-09-28 Kjell Lindstroem Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar
DK0768083T3 (da) * 1995-07-17 2003-06-23 Pfizer Anvendelse af sertralin til at behandle patienter med post myocardisk infarkt
AU724635B2 (en) * 1997-07-01 2000-09-28 Pfizer Products Inc. Gelatine encapsulated solution dosage forms of sertraline

Also Published As

Publication number Publication date
CZ20011286A3 (cs) 2001-09-12
DE69912978D1 (de) 2003-12-24
ID29845A (id) 2001-10-18
ES2209490T3 (es) 2004-06-16
YU26401A (sh) 2005-07-19
AU5643699A (en) 2000-05-01
CA2346335C (fr) 2006-04-18
IS2239B (is) 2007-05-15
HK1040199B (zh) 2005-05-27
EE04868B1 (et) 2007-08-15
CO5150213A1 (es) 2002-04-29
HRP20010263A2 (en) 2002-06-30
GEP20032969B (en) 2003-05-27
DE69912978T2 (de) 2004-04-22
HUP0104470A3 (en) 2003-12-29
EP1121107A2 (fr) 2001-08-08
NO20011829D0 (no) 2001-04-10
EP1121107B1 (fr) 2003-11-19
AP2001002119A0 (en) 2001-03-22
GC0000175A (en) 2006-03-29
UA72743C2 (en) 2005-04-15
KR20010080096A (ko) 2001-08-22
SK4582001A3 (en) 2002-02-05
CN1323202A (zh) 2001-11-21
ATE254453T1 (de) 2003-12-15
CA2346335A1 (fr) 2000-04-20
GT199900171A (es) 2001-03-28
ZA200102900B (en) 2002-05-29
EA003990B1 (ru) 2003-12-25
PT1121107E (pt) 2004-02-27
PE20001108A1 (es) 2000-10-26
OA11662A (en) 2004-12-08
EA200100285A1 (ru) 2001-10-22
DK1121107T3 (da) 2004-02-23
HK1040199A1 (en) 2002-05-31
EE200100221A (et) 2002-08-15
PL348119A1 (en) 2002-05-06
NZ510756A (en) 2003-05-30
PA8483301A1 (es) 2000-09-29
JP2002527385A (ja) 2002-08-27
KR100417200B1 (ko) 2004-02-05
WO2000021521A2 (fr) 2000-04-20
HUP0104470A2 (en) 2002-08-28
CN1184962C (zh) 2005-01-19
AU766202B2 (en) 2003-10-09
HRP20010263B1 (en) 2005-04-30
BG105434A (en) 2001-12-29
WO2000021521A3 (fr) 2000-07-20
JP3792514B2 (ja) 2006-07-05
BG65085B1 (bg) 2007-02-28
TR200101090T2 (tr) 2001-12-21
BR9914418A (pt) 2001-06-26
MY122477A (en) 2006-04-29
NO20011829L (no) 2001-06-05
AR014082A1 (es) 2001-01-31
MA26698A1 (fr) 2004-12-20
TWI228043B (en) 2005-02-21
EG23818A (en) 2007-09-19
IS5906A (is) 2001-03-23
TNSN99190A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
MA26562A1 (fr) Composes therapeutiquement actifs bases sur le remplacement bio-isosterique du catechol par l'indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant.
DZ2596A1 (fr) Associations pharmaceutiques d'amlodipine et d'atorvastatine et procédé pour leur préparation.
DZ2666A1 (fr) Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
DZ2634A1 (fr) Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ3038A1 (fr) Modulateurs nouveaux des récepteurs de glucocorticoïdes, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2074A1 (fr) Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
DZ2398A1 (fr) Composition pharmaceutique de fénofibrate présentant une biodisponibilté élevée et son procédé de préparation
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ2538A1 (fr) Tartrate d'un dipeptide substitué procédé pour sa préparation et compositions pharmaceutiques le contenant.
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2600A1 (fr) Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
DZ2679A1 (fr) Forme hydratée nouvelle d'un dérivé de thiazolidinedione procédé pour sa préparation et composition pharmaceutique la contenant.
DZ2414A1 (fr) 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2712A1 (fr) Composition de mésylate de trovafloxacine et procédé pour sa préparation.
DZ2680A1 (fr) Dérivé de thiazolidinedione nouveau procédé pour sa préparation et composition pharmaceutique le contenant.
DZ2913A1 (fr) Composition pharmaceutique concentrée liquide de sertraline et procédé pour sa préparation.
DZ3041A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procédé pour sa préparation.
DZ1946A1 (fr) Procédé pour la préparation de supports.
DZ2948A1 (fr) Dérivé d'indole nouveau, procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ3022A1 (fr) Composition pharmaceutique de résorcinol, et procédé pour sa préparation.
DZ3083A1 (fr) Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
DZ2544A1 (fr) Formes posologiques de sertraline et procédé pour leur préparation.